Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13

Journal of Clinical Investigation

Volumn 126, Issue 2, 2016, Pages 571-584

  Mpollo, Marthe Sandrine Eiymo Mwa ^a,b   Brandt, Eric B ^b,c   Shanmukhappa, Shiva Kumar ^c   Arumugam, Paritha I ^a   Tiwari, Swati ^a   Loberg, Anastacia ^a   Pillis, Devin ^a   Rizvi, Tilat ^a,c   Lindsey, Mark ^b,c   Jonck, Bart ^d   Carmeliet, Peter ^e   Kalra, Vijay K ^f   Le Cras, Timothy D ^b,c   Ratner, Nancy ^a   Wills Karp, Marsha ^g   Khurana Hershey, Gurjit K ^b,c   Malik, Punam ^a,b,c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c CCHMC   (United States)

^d ThromboGenics NV   (Belgium)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 13; LEUKOTRIENE; LEUKOTRIENE C4 SYNTHASE; PLACENTAL GROWTH FACTOR; ZILEUTON; HYDROXYUREA; PGF PROTEIN, MOUSE; PLACENTA PROTEIN;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BRONCHOALVEOLAR LAVAGE FLUID; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; EOSINOPHIL; EOSINOPHILIA; EPITHELIUM CELL; GENE EXPRESSION; INFLAMMATION; LUNG ALVEOLUS EPITHELIUM; MACROPHAGE; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT ALLERGY; SAD MOUSE; SICKLE CELL ANEMIA; ANALOGS AND DERIVATIVES; ANIMAL; ASTHMA; COMPLICATION; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; TH2 CELL;

ANEMIA, SICKLE CELL; ANIMALS; ASTHMA; DISEASE MODELS, ANIMAL; HYDROXYUREA; INTERLEUKIN-13; LEUKOTRIENES; MICE; MICE, KNOCKOUT; PLACENTA GROWTH FACTOR; PREGNANCY PROTEINS; TH2 CELLS;

EID: 84956898246     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI77250     Document Type: Article

References (77)

1. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature. 1956;178(4537):792-794.
2. Madigan C, Malik P. Pathophysiology and therapy for haemoglobinopathies; Part I: sickle cell disease. Expert Rev Mol Med. 2006;8(9):1-23.
3. Platt OS, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644.
4. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with Increased mortality in individuals with sickle cell anemia. Haematologica. 2007;92(8):1115-1118.
5. Ozbek OY, Malbora B, Sen N, Yazici AC, Ozyurek E, Ozbek N. Airway hyperreactivity detected by methacholine challenge in children with sickle cell disease. Pediatr Pulmonol. 2007;42(12):1187-1192.
6. Leong MA, Dampier C, Varlotta L, Allen JL. Airway hyperreactivity in children with sickle cell disease. J Pediatr. 1997;131(2):278-283.
7. Field JJ, et al. Airway hyperresponsiveness in children with sickle cell anemia. Chest. 2011;139(3):563-568.
8. Vendramini EC, Vianna EO, De Lucena Ângulo I, De Castro FB, Martinez JAB, Terra-Filho J. Lung function and airway hyperresponsiveness in adult patients with sickle cell disease. Am J Med Sci. 2006;332(2):68-72.
9. Sen N, Kozanoglu I, Karatasli M, Ermis H, Boga C, Eyuboglu F. Pulmonary function and airway hyperresponsiveness in adults with sickle cell disease. Lung. 2009;187(3):195-200.
10. Knight-Madden JM, Forrester TS, Lewis NA, Greenough A. Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax. 2005;60(3):206-210.
11. Koumbourlis AC, Zar HJ, Hurlet-Jensen A, Goldberg MR. Prevalence and reversibility of lower airway obstruction in children with sickle cell disease. J Pediatr. 2001;138(2):188-192.
12. Sylvester KP, Patey RA, Rafferty GF, Rees D, Thein SL, Greenough A. Airway hyperresponsiveness and acute chest syndrome in children with sickle cell anemia. Pediatr Pulmonol. 2007;42(3):272-276.
13. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood. 2006;108(9):2923-2927.
14. Boyd JH, DeBaun MR, Morgan WJ, Mao J, Strunk RC. Lower airway obstruction is associated with increased morbidity in children with sickle cell disease. Pediatr Pulmonol. 2009;44(3):290-296.
15. Cohen RT, Madadi A, Blinder MA, DeBaun MR, Strunk RC, Field JJ. Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease. Am J Hematol. 2011;86(9):756-761.
16. Glassberg JA, Chow A, Wisnivesky J, Hoffman R, DeBaun MR, Richardson LD. Wheezing and asthma are independent risk factors for increased sickle cell disease morbidity. Br J Haematol. 2012;159(4):472-479.
17. Wills-Karp M, et al. Interleukin-13: central mediator of allergic asthma. Science. 1998;282(5397):2258-2261.
18. Vargaftig BB, Singer M. Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine interleukin-13. Am J Respir Cell Mol Biol. 2003;28(4):410-419.
19. Zhu Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103(6):779-788.
20. Setty BNY, Stuart MJ. Eicosanoids in sickle cell disease: Potential relevance of neutrophil leukotriene B4 to disease pathophysiology. J Lab Clin Med. 2002;139(2):80-89.
21. Jennings JE, et al. Elevated urinary leukotriene E4 levels are associated with hospitalization for pain in children with sickle cell disease. Am J Hematol. 2008;83(8):640-643.
22. Monteiro APT, et al. Leukotriene B4 mediates neutrophil migration induced by heme. J Immunol. 2011;186(11):6562-6567.
23. Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR Jr. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol. 2003;111(1 suppl):S18-S36.
24. Knorr B, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108(3):e48.
25. Reiss TF, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, double-blind trial. Arch Intern Med. 1998;158(11):1213-1220.
26. Perelman N, et al. Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood. 2003;102(4):1506-1514.
27. Sundaram N, et al. High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood. 2010;116(1):109-112.
28. Pászty C, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997;278(5339):876-878.
29. Patel N, Sundaram N, Yang M, Madigan C, Kalra VK, Malik P. Placenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD). J Biol Chem. 2010;285(22):16713-16722.
30. Lajoie S, et al. Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat Immunol. 2010;11(10):928-935.
31. McGovern TK, Robichaud A, Fereydoonzad L, Schuessler TF, Martin JG. Evaluation of respiratory system mechanics in mice using the forced oscillation technique. J Vis Exp. 2013;(75):e50172.
32. Hou HH, Cheng SL, Liu HT, Yang FZ, Wang HC, Yu CJ. Elastase induced lung epithelial cell apoptosis and emphysema through placenta growth factor. Cell Death Dis. 2013;4:e793.
33. Janir J, Andersson S, Haglund C, Karikoski R, Lassus P. Placental growth factor and vascular endothelial growth factor receptor-2 in human lung development. Pediatrics. 2008;122(2):340-346.
34. DiPalma T, et al. The placenta growth factor gene of the mouse. Mamm Genome. 1996;7(1):6-12.
35. Tsao PN, et al. Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysema. Am J Respir Crit Care Med. 2004;169(4):505-511.
36. Patel N, Gonsalves CS, Yang M, Malik P, Kalra VK. Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease. Blood. 2009;113(5):1129-1138.
37. Patel N, Kalra VK. Placenta growth factorinduced early growth response 1 (Egr-1) regulates hypoxia-inducible factor-1alpha (HIF-1α) in endothelial cells. J Biol Chem. 2010;285(27):20570-20579.
38. Laitinen LA, Haahtela T, Vilkka V, Lee TH, Spur BW. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet. 1993;341(8851):989-990.
39. Gauvreau GM, Parameswaran KN, Watson RM, O'Byrne PM. Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma. Am J Respir Crit Care Med. 2001;164(8):1495-1500.
40. Nabe T, Yamashita K, Miura M, Kawai T, Kohno S. Cysteinyl leukotriene-dependent interleukin-5 production leading to eosinophilia during late asthmatic response in guinea-pigs. Clin Exp Allergy. 2002;32(4):633-640.
41. Guajardo JR, et al. Altered gene expression profiles in nasal respiratory epithelium reflect stable versus acute childhood asthma. J Allergy Clin Immunol. 2005;115(2):243-251.
42. Patel N, Gonsalves CS, Malik P, Kalra VK. Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxiainducible factor-1α. Blood. 2008;112(3):856-865.
43. Thivierge M, Staňková J, Rola-Pleszczynski M. IL-13 and IL-4 up-regulate cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages. J Immunol. 2001;167(5):2855-2860.
44. Chibana K, Ishii Y, Asakura T, Fukuda T. Upregulation of cysteinyl leukotriene 1 receptor by IL-13 enables human lung fibroblasts to respond to leukotriene C4 and produce eotaxin. J Immunol. 2003;170(8):4290-4295.
45. Jackson SE, Holloway JW, Warner JA, Sampson AP. Interleukin-13, but not indomethacin, increases cysteinyl-leukotriene synthesis in human lung macrophages. J Allergy (Cairo). 2012;2012:348741.
46. Doherty TA, Khorram N, Lund S, Mehta AK, Croft M, Broide DH. Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production. J Allergy Clin Immunol. 2013;132(1):205-213.
47. Tordjman R, et al. Erythroblasts are a source of angiogenic factors. Blood. 2001;97(7):1968-1974.
48. Selvaraj SK, Giri RK, Perelman N, Johnson C, Malik P, Kalra VK. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood. 2003;102(4):1515-1524.
49. Wills-Karp M, Ewart SL. The genetics of allergen-induced airway hyperresponsiveness in mice. Am J Respir Crit Care Med. 1997;156(4):S89-S96.
50. Ewart SL, et al. Quantitative trait loci controlling allergen-induced airway hyperresponsiveness in inbred mice. Am J Respir Cell Mol Biol. 2000;23(4):537-545.
51. Manci EA, Hillery CA, Bodian CA, Zhang ZG, Lutty GA, Coller BS. Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease. Blood. 2006;107(4):1651-1658.
52. Bobic S, et al. Placental growth factor contributes to bronchial neutrophilic inflammation and edema in allergic asthma. Am J Respir Cell Mol Biol. 2012;46(6):781-789.
53. Pritchard KA, et al. Effects of experimental asthma on inflammation and lung mechanics in sickle cell mice. Am J Respir Cell Mol Biol. 2012;46(3):389-396.
54. McKinley L, Kim J, Bolgos G, Siddiqui J, Remick D. Allergens induce enhanced bronchoconstriction and leukotriene production in C5 deficient mice. Respir Res. 2006;7:129.
55. Irvin CG, Tu YP, Sheller JR, Funk CD. 5-Lipoxygenase products are necessary for ovalbumininduced airway responsiveness in mice. Am J Physiol. 1997;272(6 pt 1):L1053-L1058.
56. Peebles RS, et al. Allergen-induced airway hyperresponsiveness mediated by cyclooxygenase inhibition is not dependent on 5-lipoxygenase or IL-5, but is IL-13 dependent. J Immunol. 2005;175(12):8253-8259.
57. Shin K, Hwang JJ, Kwon BI, Kheradmand F, Corry DB, Lee SH. Leukotriene enhanced allergic lung inflammation through induction of chemokine production. Clin Exp Med. 2015;15(3):233-244.
58. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990;323(10):645-655.
59. Bellik L, Vinci MC, Filippi S, Ledda F, Parenti A. Intracellular pathways triggered by the selective FLT-1-agonist placental growth factor in vascular smooth muscle cells exposed to hypoxia. Br J Pharmacol. 2005;146(4):568-575.
60. Pope SM, Zimmermann N, Stringer KF, Karow ML, Rothenberg ME. The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. J Immunol. 2005;175(8):5341-5350.
61. Hogan SP, Matthaei KI, Young JM, Koskinen A, Young IG, Foster PS. A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5. J Immunol. 1998;161(3):1501-1509.
62. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199-204.
63. Eum S-Y, Maghni K, Tolloczko B, Eidelman DH, Martin JG. IL-13 may mediate allergeninduced hyperresponsiveness independently of IL-5 or eotaxin by effects on airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2005;288(3):L576-L584.
64. Kuperman DA, et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med. 2002;8(8):885-889.
65. Fischer C, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131(3):463-475.
66. Li B, et al. Elevated PLGF contributes to smallcell lung cancer brain metastasis. Oncogene. 2013;32(24):2952-2962.
67. Cheng S-L, Wang H-C, Yu C-J, Yang P-C. Increased expression of placenta growth factor in COPD. Thorax. 2008;63(6):500-506.
68. Belcher JD, et al. Transgenic sickle mice have vascular inflammation. Blood. 2003;101(10):3953-3959.
69. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11(2):129-151.
70. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106(3):411-420.
71. Kaul DK, Liu X-D, Choong S, Belcher JD, Vercellotti GM, Hebbel RP. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol. 2004;287(1):H293-H301.
72. Vichinsky EP, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342(25):1855-1865.
73. Knight-Madden JM, Barton-Gooden A, Weaver SR, Reid M, Greenough A. Mortality, asthma, smoking and acute chest syndrome in young adults with sickle cell disease. Lung. 2013;191(1):95-100.
74. Koumbourlis AC, Hurlet-Jensen A, Bye MR. Lung function in infants with sickle cell disease. Pediatr Pulmonol. 1997;24(4):277-281.
75. Koumbourlis AC, Lee DJ, Lee A. Longitudinal changes in lung function and somatic growth in children with sickle cell disease. Pediatr Pulmonol. 2007;42(6):483-488.
76. Kramer EL, et al. Early growth response-1 suppresses epidermal growth factor receptormediated airway hyperresponsiveness and lung remodeling in mice. Am J Respir Cell Mol Biol. 2009;41(4):415-425.
77. Martin LJ, et al. Functional variant in the autophagy-related 5 gene promotor is associated with childhood asthma. PLoS One. 2012;7(4):e33454.